Clinical trials: Gemcitabine
Breast Cancer
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
The main purpose of this study is to see whether CDX-011 is effective in treating patients who have advanced breast cancer that makes a protein called glycoprotein NMB (GPNMB), and who have already received (or were not…
- Trial name
- EMERGE (NCT01156753)
- Testing
- CDX-011, "Investigator's Choice" chemotherapy
- Where
- 24 sites in United States
- Volunteers
- 120 people
- Sponsor
- Celldex Therapeutics
Pancreatic Adenocarcinoma
Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma
AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer.
- Trial name
- NCT00327327
- Testing
- imexon, gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 105 people
- Sponsor
- AmpliMed Corporation
Metastatic Cancer, Cancer
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors
This is a Phase 1a/b multicenter, open-label, non-randomized, dose-escalation study to examine the dose limiting toxicities (DLT) of BPM31510 administered as a 144-hour continuous intravenous (IV) infusion as…
- Conditions
- Metastatic Cancer, Cancer, Solid Tumor
- Trial name
- NCT01957735
- Testing
- BP31510 monotherapy, BP31510 in combination with chemotherapy
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- BPGbio
Triple Negative Breast Neoplasms
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).
- Trial name
- IMpassion132 (NCT03371017)
- Testing
- Atezolizumab, Gemcitabine, Capecitabine
- Where
- 124 sites in United States, Argentina and 26 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in…
- Trial name
- NCT00027989
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Advanced Pancreatic Cancer
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
This trial is the cohort C part of a multicenter, open label Phase Ib/II clinical study evaluating the preliminary efficacy, safety, and tolerability of LM-108 combined with anti-tumor therapy in patients with advanced solid…
- Trial name
- NCT06821503
- Testing
- LM-108 injection, Penpulimab injection, Paclitaxel for injection (albumin bound)
- Where
- 16 sites in China
- Volunteers
- 72 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ovarian Cancer, Peritoneal Carcinomatosis
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
- Conditions
- Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
- Trial name
- NCT02759588
- Testing
- Olvi-Vec, Platinum-doublet with or without bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Genelux Corporation
Squamous Non-small Cell Lung Cancer
A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
The purpose of the Phase 1b portion of the study is to investigate how the body tolerates necitumumab, in combination with gemcitabine and cisplatin chemotherapy as first line treatment in participants with Stage IV squamous…
- Trial name
- NCT01763788
- Testing
- Necitumumab, Gemcitabine, Cisplatin
- Where
- 20 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, CRC
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06445062
- Testing
- RMC-6236, mFOLFOX6 regimen, bevacizumab
- Where
- 32 sites in United States
- Volunteers
- 1,130 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Pancreatic Cancer
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination…
- Trial name
- ARC-8 (NCT04104672)
- Testing
- AB680, Zimberelimab, Nab-paclitaxel
- Where
- 9 sites in United States
- Volunteers
- 196 people
- Sponsor
- Arcus Biosciences, Inc.
Non-small Cell Lung Cancer Stage IV
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
Primary Objective: to assess the objective response rate (ORR) of Iniparib (SAR240550) administered as a 60-min intravenous infusion twice weekly, when combined to gemcitabine/cisplatin chemotherapy regimen (GCS) as well as with…
- Trial name
- NCT01086254
- Testing
- Iniparib, gemcitabine, cisplatin
- Where
- 14 sites in France, Germany and 3 more
- Volunteers
- 119 people
- Sponsor
- Sanofi
Metastatic Pancreatic Cancer
Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer
Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine
- Trial name
- NCT00326911
- Testing
- cetuximab, bevacizumab, gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 61 people
- Sponsor
- Eli Lilly and Company
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Urologic Neoplasms, Carcinoma, Transitional Cell
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium
- Trial name
- NCT00191971
- Testing
- Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Locally Advanced or Metastatic Pancreatic Cancer
Masitinib Plus Gemcitabine in Pancreatic Cancer
The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have…
- Trial name
- NCT03766295
- Testing
- Masitinib, Gemcitabine
- Where
- 9 sites in Belgium, France and 6 more
- Volunteers
- 377 people
- Sponsor
- AB Science
Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer
PHASE 1 TRIAL OF Lm-LLO-TT AND GEMCITABINE IN UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA
ClinicalTrials.gov Brief Summary This Phase 1, open-label, first-in-human study is designed to evaluate the safety, tolerability, and recommended dose of intraperitoneal (IP) administration of Lm-LLO-TT in combination with…
- Conditions
- Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT07828236
- Testing
- Lm-LLO-TT
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Loki Therapeutics, Inc.
Pancreatic Cancer
CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population).
- Trial name
- NCT05052567
- Testing
- CEND-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Urologic Neoplasms
A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
- Trial name
- NCT00034593
- Testing
- ALIMTA, gemcitabine
- Where
- 9 sites in Finland, France and 1 more
- Sponsor
- Eli Lilly and Company
Cancer
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
This is a Phase IIa, open-label, single-arm, multi-center study to evaluate the efficacy and safety of orally administered MEK inhibitor trametinib as the second line in subjects with advanced or metastatic biliary tract cancers…
- Trial name
- NCT01943864
- Testing
- Trametinib (single tablet), Trametinib (Multiple tablet)
- Where
- 5 sites in Japan
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
HER2 Gene Mutation
IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors
The study aims to evaluate the efficacy and safety of IAH0968 in combination with gemcitabine and cisplatin for the treatment of HER2-positive unresectable advanced/metastatic malignant tumors and cholangiocarcinoma.
- Trial name
- NCT05991518
- Testing
- Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin
- Where
- China
- Volunteers
- 136 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.